20
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
T9706 | BTK inhibitor 17 | BTK | |
BTK inhibitor 17 is a potent irreversible BTK inhibitor (IC50 = 2.1 nM). BTK inhibitor 17 can be used in rheumatoid arthritis studies. | |||
T10629 | Btk inhibitor 2 | BGB-3111 analog | BTK |
Btk inhibitor 2 (BGB-3111 analog) is a BTK inhibitor. | |||
T35330 | BTK inhibitor 1 | BTK | |
BTK inhibitor 1 (Compound 27) is a BTK inhibitor (IC50: 0.11 nM) with an inhibitory effect on B-cell activation in hWB with an IC50 of 2 nM. | |||
TQ0230 | BTK IN-1 | SNS062 analog | BTK |
BTK IN-1 (SNS062 analog) (SNS062 analog) is an effective BTK inhibitor (IC50: <100 nM). | |||
T60542 | BTK-IN-16 | BTK | |
BTK-IN-16 is a potential inhibitor of wild-type BTK and C481S mutants.BTK-IN-16 can be used to study various autoimmune diseases and cancers caused by BTK. | |||
T40185 | BTK inhibitor 19 | ||
BTK inhibitor 19 is a highly selective, covalent BTK inhibitor ( IC 50 = 2.7 nM). | |||
T39612 | BTK-IN-5 | ||
BTK-IN-5 is a covalent inhibitor of Bruton's tyrosine kinase (BTK) designed for the treatment of medical conditions including cardiovascular diseases, respiratory diseases, inflammation, and diabetes. | |||
T9813 | JAK3/BTK-IN-2 | JAK , BTK | |
JAK3/ BTk-in-2 is a potent JAK3/BTK inhibitor. JAK3/ BTk-in-2 inhibits both BTK and JAK3, which are two important targets IN autoimmune diseases. JAK3/ BTk-in-2 simultaneously inhibits the BTK/JAK3 signaling pathway, sho... | |||
T9814 | JAK3/BTK-IN-1 | JAK , BTK | |
JAK3/ BTk-in-1 is a dual JAK3/BTK inhibitor that specifically targets and inhibits Janus kinase 3 (JAK3) and Bruton's tyrosine kinase (BTK), two important targets in autoimmune diseases. JAK3/ BTk-in-1 simultaneously inh... | |||
T10628 | BTK inhibitor 13 | Others | |
BTK inhibitor 13 (compound 8) is an effective and selective BTK inhibitor(IC50: 1.2 nM). | |||
T36297 | Btk inhibitor 1 hydrochloride | ||
Btk inhibitor 1 Hcl is a pyrazolo[3,4-d]pyrimidine derivative as a Btk kinase inhibitor.IC50 value:Target: BtkFrom PCT Int. Appl. (2012), WO 2012158843 A2 20121122. [1]. PCT Int. Appl. (2012), WO 2012158843 A2 20121122. | |||
T14956 | CHMFL-BTK-01 | BTK | |
CHMFL-BTK-01 is an irreversible inhibitor of BTK (IC50: 7 nM) and also potently inhibits BTK Y223 auto-phosphorylation. | |||
T10627 | BTK inhibitor 10 | Others | |
BTK inhibitor 10 is a potent and orally active BTK inhibitor. It has the potential for rheumatoid arthritis treatment. | |||
T62716 | BTK-IN-10 | ||
BTK-IN-10 is a potent inhibitor of BTK, acting on wild-type BTK (IC50<5 nM) or mutant BTK (C481S) (IC50<5 nM). | |||
T75124 | BTK-IN-24 | ||
BTK-IN-24 (compound 195) is a potent BTK inhibitor via a ubiquitin proteolytic pathway [1] . | |||
T63810 | BTK-IN-7 | ||
BTK-IN-7 is a selective and potent BTK inhibitor with an IC50 value of 4.0 nM. BTK-IN-7 exhibits high selectivity at both the enzymatic (ITK>250-fold, EGFR>2500-fold) and cellular levels (ITK>227-fold, EGFR27-fold). BTK-... | |||
T63173 | BTK-IN-8 | ||
BTK-IN-8 is a potent, selective, peripheral covalent BTK inhibitor with an IC50 value of 0.22 nM and a Kd value of 0.91 nM. BTK-IN-8 exhibits good potency in whole blood CD69 cells with an IC50 value of 0.029 μM. | |||
T73276 | BTK-IN-23 | ||
BTK-IN-23 is a BTK inhibitor with an IC50 value of 12.8 nM, demonstrating kinase selectivity superior to Ibrutinib [1]. It also effectively inhibits BLX and BMX, with IC50 values of 35.6 nM and 5.7 nM, respectively. | |||
T72664 | BTK inhibitor 20 | ||
BTK inhibitor 20 is a potent BTK inhibitor with an IC 50 of 8 nM . | |||
T73275 | BTK-IN-22 | ||
BTK-IN-22, a BTK inhibitor (IC 50: 0.9 nM), also exhibits inhibition against BLX and BMX with IC 50 values of 1.4 and 1.2 nM, respectively. Demonstrating enhanced kinase selectivity, BTK-IN-22 outperforms Ibrutinib in th... |